Skip to main content
Premium Trial:

Request an Annual Quote

Iverson, Johns Hopkins Ink Deal to Commercialize MDx for Heart Disease, Infertility

NEW YORK (GenomeWeb News) – Iverson Genetic Diagnostics said today it has received global exclusive rights from Johns Hopkins University School of Medicine to commercialize a molecular diagnostic test.

The licensing agreement grants Iverson rights to a test for assessing cardiovascular risk in men and women and infertility risk in women. According to Iverson, research by Annabelle Rodriguez-Oquendo at the School of Medicine suggests that mutations within the scavenger receptor class B type 1 (SR-B1) gene is associated with heart disease risk and hormonal and fertility problems in women.

"The importance of finding gene variants that affect the metabolism of cholesterol, especially the healthy fraction, and hormones — hence causing disease — is incredibly important for personalized medicine," Leroy Hood, a co-founder of the Institute for Systems Biology and a member of Iverson's board, said in a statement. "This agreement between Iverson and Johns Hopkins is a wonderful example of a diagnostic test that could significantly improve the health of many patients throughout the world."

Financial and other terms were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.